PURPOSE: New prognostic markers are needed for malignant melanoma. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activating mutations in BRAF/NRAS oncogenes are often detected in melanoma. The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma. EXPERIMENTAL DESIGN: The expression of iNOS and COX-2 in metastatic lymph nodes from 21 rapidly progressing (OS from date of diagnosis of stage III disease < or =14 months) and 17 slowly progressing (OS > or =60 months) stage III cutaneous melanoma patients was examined by immunohistochemistry. The presence of BRAF/NRAS mutations was analyzed using direct DNA sequencing. Chi2 exact trend test and logistic regression analysis were used for statistical analysis. RESULTS: Both iNOS (P = 0.002) and COX-2 (P = 0.048) alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly (P = 0.013) correlated with BRAF mutation frequency. Furthermore, the odds ratio (OR) with respect to OS of iNOS (OR = 10.4) was higher than that of COX-2 (OR = 5.6) and was stable in the multivariate analysis of OS together with disease stage IIIB/C, ulceration, number of metastatic lymph nodes, and Breslow tumor thickness. CONCLUSION: Our data show that iNOS is an independent and stronger prognostic factor for OS in stage III malignant cutaneous melanoma than COX-2.
PURPOSE: New prognostic markers are needed for malignant melanoma. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activating mutations in BRAF/NRAS oncogenes are often detected in melanoma. The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma. EXPERIMENTAL DESIGN: The expression of iNOS and COX-2 in metastatic lymph nodes from 21 rapidly progressing (OS from date of diagnosis of stage III disease < or =14 months) and 17 slowly progressing (OS > or =60 months) stage III cutaneous melanomapatients was examined by immunohistochemistry. The presence of BRAF/NRAS mutations was analyzed using direct DNA sequencing. Chi2 exact trend test and logistic regression analysis were used for statistical analysis. RESULTS: Both iNOS (P = 0.002) and COX-2 (P = 0.048) alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly (P = 0.013) correlated with BRAF mutation frequency. Furthermore, the odds ratio (OR) with respect to OS of iNOS (OR = 10.4) was higher than that of COX-2 (OR = 5.6) and was stable in the multivariate analysis of OS together with disease stage IIIB/C, ulceration, number of metastatic lymph nodes, and Breslow tumor thickness. CONCLUSION: Our data show that iNOS is an independent and stronger prognostic factor for OS in stage III malignant cutaneous melanoma than COX-2.
Authors: Julie A Ellerhorst; A H Diwan; Shyam M Dang; Deon G Uffort; Marilyn K Johnson; Carolyn P Cooke; Elizabeth A Grimm Journal: Oncol Rep Date: 2010-04 Impact factor: 3.906
Authors: Suhendan Ekmekcioglu; Michael A Davies; Keiji Tanese; Jason Roszik; Myung Shin-Sim; Roland L Bassett; Denái R Milton; Scott E Woodman; Victor G Prieto; Jeffrey E Gershenwald; Donald L Morton; Dave S Hoon; Elizabeth A Grimm Journal: Clin Cancer Res Date: 2016-01-18 Impact factor: 12.531
Authors: Sun-Hee Kim; Yuuri Hashimoto; Sung-Nam Cho; Jason Roszik; Denái R Milton; Fulya Dal; Sangwon F Kim; David G Menter; Peiying Yang; Suhendan Ekmekcioglu; Elizabeth A Grimm Journal: Pigment Cell Melanoma Res Date: 2016-03-15 Impact factor: 4.693
Authors: Zhen Yang; Bobbye Misner; Haitao Ji; Thomas L Poulos; Richard B Silverman; Frank L Meyskens; Sun Yang Journal: Antioxid Redox Signal Date: 2013-01-18 Impact factor: 8.401
Authors: Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans Journal: BMC Cancer Date: 2010-08-30 Impact factor: 4.430